Home Cart Sign in  
Chemical Structure| 1190197-97-7 Chemical Structure| 1190197-97-7

Structure of DLin-KC2-DMA
CAS No.: 1190197-97-7

Chemical Structure| 1190197-97-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

D-Lin-MC3-DMA is an ionizable cationic lipid that can be used as a carrier for delivering siRNA.

Synonyms: KC2

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of DLin-KC2-DMA

CAS No. :1190197-97-7
Formula : C43H79NO2
M.W : 642.09
SMILES Code : CCCCC/C=C\C/C=C\CCCCCCCCC1(CCCCCCCC/C=C\C/C=C\CCCCC)OCC(CCN(C)C)O1
Synonyms :
KC2
MDL No. :MFCD31813697
InChI Key :LRFJOIPOPUJUMI-KWXKLSQISA-N
Pubchem ID :44464860

Safety of DLin-KC2-DMA

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319
Precautionary Statements:P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313

Isoform Comparison

Biological Activity

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6 mice Healthy mouse model Intravenous injection 0.3 mg/kg LNPs Single injection, observed at 4 and 24 hours Evaluate transfection efficiency of PLE-LLNPs and HA-LLNPs in liver and spleen Proc Natl Acad Sci U S A. 2024 Mar 12;121(11):e2307809121
CD1 mice Liver cells (hepatocytes, LSECs, KCs) Intravenous injection 0.5 mg/kg LNPs Single dose, analyzed at 5 and 24 hours post-injection To compare the in vivo mRNA delivery and protein expression efficiency of DLin-KC2-DMA with MC3 and DD, showing intermediate protein expression levels for KC2 despite similar mRNA and lipid uptake. Proc Natl Acad Sci U S A. 2023 Dec 12;120(50):e2310491120
Syrian hamsters SARS-CoV-2 B.1.617.2 and BA.5 variant infection model Intramuscular injection 5 or 20 μg Two immunizations, 28 days apart To evaluate the immunogenicity and protective efficacy of DLin-KC2-DMA LNP vaccine in a hamster model. Results showed that LNP encapsulation significantly enhanced antibody responses and provided effective protection against homologous and heterologous SARS-CoV-2 variants. Mol Ther Methods Clin Dev. 2024 Aug 19;32(3):101325

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.56mL

0.31mL

0.16mL

7.79mL

1.56mL

0.78mL

15.57mL

3.11mL

1.56mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories